Investing

PHI Group, Inc. Common Stock PHIL Stock News

PHI Group, Inc. Common Stock (OTCMKTS: PHIL) is having a relatively strong day in the market today, and for good reason. The company announced that it will be employing new power power systems at a key renewable power plant. Of course, this led to excitement among investors, prompting gains in the value of the stock. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (11:14), PHIL is trading at $0.065 per share after a gain of $0.003 per share or 5.61% thus far today.





PHIL Makes Key Announcement Surrounding Renewable Power Plant

As mentioned above, PHI Group is having a strong day in the market today after an announcement made yesterday caused excitement among investors. According to the announcement, the company, in conjunction with Hung Vuong Export Import and Construction JSC, has given notice to the Provincial People’s Committee of Yen Bai Province, Vietnam, to preplace the previously contemplated kinetic energy and employ Aquarius Power, Inc.’s systems for the renewable power plant project in Yen Binh District, Yen Bai Province.




PHIL has a strong relationship wit AQP. In fact, the company has invested in AQP to become a strategic shareolder and plans on continuing to make additional investments in the near future. The companies have also agreed that PHIL will have an exclusive right to sublicense, sell, build, own and/or operate the AQP energy systems in Vietnam.

The Aquarius Wave Energy System is a land-based wave energy system that uses a combination of gravity and buoyancy found within the interaction between air and water to produce power. The process is designed to produce power that can be used to generate electricity and/or produce potable water. In a statement, Ha Hoang Vuong, Chirman of HVJSC, had the following to offer…

We are excited to work with PHIL to bring this amazing technology to Yen Bai Province and are confident that we can provide affordable baseload renewable energy to both rural and urban areas throughout vietnam in the near future.”

The above statement was followed up by Henry Fahman, Chairman and CEO of PHIL. Here’s what he had to say…

We are delighted to partner with AQP and HVJSC and look forward to installing this innovative technology for the first 60-MW cluster in Yen Binh District. PHIL also has plans to launch a similar project in Eastern Europe soon.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on PHIL. In particular, we’re interested in following the company’s ongoing work not only in the Yen Binh District, but around the world as the company continues to expand. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Helios and Matheson Analytics Inc HMNY Stock News

Helios and Matheson Analytics Inc (NASDAQ: HMNY) is having an overwhelmingly strong day in the market today, and for good reason. It seems as though investors are starting to pay attention to the exponential growth the company is seeing with regard to its user base. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (11:24), HMNY is trading at $7.73 per share after a gain of $1.87 per share or 31.98% thus far today.





HMNY Gains As User Growth Soars

As mentioned above, Helios and Matheson Analytics is having an incredible day in the market today after the company recently announced massive growth in its user base. The company is a leading independent equity research and corporate access firm that provides information technology services and solutions ranging from big data to artificial intelligence, social listening and consumer-centric technology.




Pretty recently, HMNY announced that it would be acquiring a majority interest in MoviePass, a system that enables subscribers to unlimited movies in theaters for a small monthly fee of just $9.95. Days ago, it was announced by HMNY that subscriptions have grown from around 20,000 to over 400,000 since the acquisition.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on HMNY. In particular, we’re interested in following the growth surrounding MoviePass as the company seems to be doing overwhelmingly well at the moment. On top of that, we’re also going to be watching RedZone Map very closely as the product has tremendous potential to be a massive driver of revenue moving forward. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 269
MannKind Corporation MNKD Stock News

MannKind Corporation (NASDAQ: MNKD) is having an interesting day in the market this morning. Early on, the stock was up more than 3%, but since, it has fallen slightly in the red. Nonetheless, there is some big news on the horizons, so we are excited that our partners at Trade Ideas brought this stock to our attention today. Currently (10:13), MNKD is trading at $1.93 per share after a gain of $0.01 per share or 0.51% thus far today.





MNKD May Fly Next Month

As mentioned above, MannKind Corporation is all over the place today. However, as we near the middle of next month, the stock could fly as the next clinical catalyst comes to light. That’s because the company is currently working on a Phase 4 clinical study that is coming to an end. In fact, it’s expected that investors will hear an update with regard to the trial on October 15th.




The Phase 4 clinical trial surrounds inhaled technosphere insulin in Diabetes Melitus, Type 1. The trial is an investigator-initiated, prospective, randomized, multicenter, parallel, open-label, bilot clinical trial that’s designed to evaluate the efficacy of TI for PPBG, PPGE, and time-in-range on CGM download in patients with type 1 diabetes. TI (Technosphere Insulin) is already approved by the FDA for patients with diabetes.

The MNKD Phase 4 study is a multi-center study which follows 60 patients with T1D, A1c values between 6.5% and 10%. The patients included in the study are randomized in a 1:1 fashion to TI or NL. The patients that are randomized into the NL arm of the study will be using their usual prandial insulin dose before meals. However, patients that are randomized into the TI arm will be instructed to dose before meals and take necessary corrections at 1 and 2 hours after meals in order to optimize PPBG.

While technosphere insulin has already been approved by the FDA, it is hoped that this study will improve the labeling surrounding the treatment, leading to stronger sales. Also, MNKD is looking to prove several primary and secondary outcomes. Here are the results they are expecting:

Primary Endpoints

  • Improved time in range (70-180 mg/dl) with TI on CGM [Time Frame: 4 weeks]
  • Better post-prandial glucose excursion (1-4 hours after meals) with TI [Time Frame: 4 weeks]

Secondary Endpoints

  • Less glucose variability (GV) (standard deviation and/or coefficient variation) [Time Frame: 4 weeks]
  • The area under the curve calculation (AUC) in the PPBG and PPGE [Time Frame: 4 weeks]
  • Change in HbA1c in one-month treatment [Time Frame: 4 weeks]
  • above the target time (>180 mg/dl) on CGM [Time Frame: 4 weeks]
  • hypoglycemia frequency (below the target <70, <60, <50 mg/dl) on CGM [Time Frame: 4 weeks]

For more information with regard to the clinical trial, click here!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will keep a close eye on MNKD. In particular, we’re interested in learning the outcomes of the study mentioned above. We’re also interested in following the sales force along and excited for the potential new labeling to lead to stronger sales. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 311
Savara Inc SVRA Stock News

Savara Inc (NASDAQ: SVRA) is having an overwhelmingly strong start to the trading session in the pre-market this morning, and for good reason. Not only did the company announce yesterday that it would be providing a key presentation relatively soon, Jefferies has initiated coverage with an overwhelmingly favorable view. Of course, this led to excitement among investors, pushing the stock toward the top and prompting our partners at Trade Ideas to alert us to the gains. At the moment (9:18), SVRA is trading at $10.37 per share after a gain of 9.50% thus far today.





SVRA Gains On Jefferies Coverage & Coming Presentation

As mentioned above, Savara is having an overwhelmingly strong start to the trading session this morning after it was announced that Jefferies has initiated coverage on the stock. Analysts at Jefferies have rated the stock a buy, offering a $20 price target. That’s an incredible target considering that the stock closed at $9.47 yesterday. This means that Jefferies sees a potential 111.19% upside!




However, the coverage from Jefferies isn’t the only news that we’ve seen from the company as of late. In fact, yesterday, the company announced through a press release that it would be providing a presentation at the Cantor Fitzgerald 2017 Global Healthcare Conference. The conference will be held on Wednesday September 27, 2017 at 11:30 a.m. Eastern Time. The conference will take place at the InterContinental New York Barclay Hotel in New York. If you’re interested in listening to the live audio webcast, you can do so by going to the company’s website, www.savarapharma.com. The webcast will also be available on the company’s website for 30 days.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SVRA. In particular, we’re interested in following the company to see if Jefferies was correct with their overwhelmingly positive expectations. We’re also excited for the coming presentation and will be reporting on that shortly after the presentation ends. So, stick with us… we’ll be following the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1618
Gevo Inc. GEVO Stock News

Gevo, Inc. (NASDAQ: GEVO) is having an overwhelmingly strong day in the market today, and for good reason. Yesterday, U.S. Secretary of Energy Rick Perry made a key announcement with regard to biofuels and biorefineries. This led to excitement among investors, causing gains in the value of the stock. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (11:04), GEVO is trading at $0.74 per share after a gain of $0.14 per share (23.14%) thus far today.





GEVO Gains On Department of Energy Moves

As mentioned above, Gevo is having an incredibly strong start to the trading session this morning after an announcement made by Rick Perry, U.S. Secretary of Energy. Perry announced that the Department of Energy (DOE) has selected 8 projects to negotiate for up to $15 million in total DOE funding. The funding is aimed at optimizing integrated biorefineries. Ultimately, the goal is to solve critical research and development challenges encountered for successful scale-up and reliable operation of integrated biorefinaries. It is expected that through this research, capital expenses and operating expenses will be decreased surrounding the production of biofuels. In a statement, Rick Perry had the following to offer:




The Integrated Biorefinery Optimization effort is a prime example of how the Department of Energy can leverage its resources to help solve real-world issues facing biorefineries… These projects have the potential to increase the efficiency of producing biofuels and bioproducts, enabling the United States to better utilize its abundant biomass resources, boost economic development, and advance U.S. competitiveness in the global energy market.”

While the eight companies that are involved in these plans have not been named, there is speculation that GEVO is one of them, and for good reason. After all, Gevo is a company that has made it further along than any other in the biorefinery space. So, it only makes sense that they would be part of this research!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on GEVO. In particular, we’re interested in learning more about the funding from the government and whether or not the company is part of these plans. We’re also interested in following the company’s ongoing efforts to scale up and mass market their biofuel. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Seadrill Ltd SDRL Stock News

Seadrill Ltd (NYSE: SDRL) is having an overwhelmingly rough day in the market today after various reports have surfaced that some bondholders are looking to take their fight against the company to the legal level with regard to its plans to restructure. Of course, this led to concern among investors, causing declines in the value of the stock and prompting our partners at Trade Ideas to alert us to the drop. At the moment (10:32), SDRL is trading at $0.40 per share after a loss of $0.08 per share (15.78%) thus far today.





SDRL Restructuring Plans

As mentioned above, Seadrill is having an incredibly rough day in the market after reports have surfaced that bondholders have gotten together to fight the company’s restructuring plans. According to various reports, some bondholders have hired Strook & Strook & Lavan LLP as legal counsel to fight against the company’s plans to restructure under Chapter 11 bankruptcy.




Last week, SDRL announced that it had filed for Chapter 11 bankruptcy protection after closing a deal with banks and a minority bondholder. Through the deal, the company would receive approximately $1 billion in new capital as well as extend or convert around $8 billion in loans into equity in the company. The funds would be received through $860 million in secured loans as well as an additional $200 million as the result of the sale of new equity.

Unfortunately, however, this restructuring plan would happen at the detriment of investors. In fact, if the agreement does move forward, current shareholders will be left with only about 2% of the post-restructuring company. Nonetheless, shareholders seemed to be excited about the news, as the restructuring plan would put SDRL on strong financial footing. However, should the bondholders have their way, the restructuring plan will be blocked and the c-suite will be back to the drawing board!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SDRL. In particular, we’re interested in following the story surrounding restructuring as well as seeing if the plans actually take place. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 318
ITUS Corp. ITUS Stock News

ITUS Corp (NASDAQ: ITUS) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company provided its shareholders with a clinical update and informing them of a coming corporate update. Of course, this caused excitement among investors, leading to gains in the value of the stock. As is usually the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:53), ITUS is trading at $2.07 per share after a gain of $0.14 per share or 7.25% thus far today.





ITUS Gains On Updates

As mentioned above, ITUS is having an incredibly strong start to the trading session this morning after providing investors with a clinical update while informing them of a coming corporate update. The corporate update will come by way of its Annual Meeting of Stockholders, which will be held tomorrow, September 22, 2017.

The company said that its wholly owned subsidiary, Anixa Diagnostics recently renewed its research agrement with The Wistar Institute for continued development of CcheckTM. Ccheck is the company’s early cancer detection technology. The company also reminded investors of the recently announced issuance of US Patent 9,739,783, which covers the company’s technology for cancer detection.




Looking ahead of the cancer diagnostics development plans at ITUS, the company also plans on expanding its fight against cancer with an exclusive option agreement with The Wistar Institute. The license agreement covers intellectual property surrounding a proprietary Chimeric: Antigen Receptor T-Cells (Car-T) technology. This technology is focused on Ovarian Cancer, but has the potential for future indications in prostate, pancreatic, and other cancers as well. In a statement, Dr. Amit Kumar, President and CEO at ITUS, had the following to offer…

We continue to make progress in our R&D efforts as we work with our partners, MD Anderson, U. Pennsylvania’s Abramson Cancer Center, Deleware Valley Urology, Virtua Hospitals, and others. CcheckTM, which has demonstrated 91% sensitivity and specificity in a preliminary study, continues to perform at that level or better.

The results of these studies to date have been consistent with the superior performance of our data in our own clinical studies. When completed, we plan to disclose the results of these studies in concert with each individual collaborator.

We are very pleased with this exclusive option to our long-term partner’s innovative Car-T technology. Car-T technology has been the subject of much attention recently as pioneer Car-T company Kite Pharma recently announced its acquisition by Gilead, and the FDA has recently approved Novartis’s KymriahTM for treatment of B-cell Acute Lymphoblastic Leukemia. In addition to our ongoing discussions with The Wistar Institute, we are concurrently negotiating with one of the country’s top cancer centers to further develop the technology, aiming to complete the studies necessary to submit to the US FDA, enabling human testing on ovarian cancer patients.

Car-T technology has shown tremendous promise in B-cell cancers, but very little progress has been made on solid tumors, like ovarian cancer. The Wistar Institute’s approach utilizes Car-T and their published animal studies show great efficacy… We hope to update our shareholders on all of these and other initiatives in the coming months.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ITUS. In particular, we’re interested in following the ongoing work surrounding CarT the company is doing to bring innovative new options to the oncology market. Nonetheless, we’ll continue to follow the story closely and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 617
Akari Therapeutics PLC (ADR) AKTX Stock News

Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) is having an incredibly strong start to the trading session in the pre-market hours and for good reason. The company announced that it plans to advance a key pipeline treatment to Phase III clinical studies. Of course, this led to excitement among investors, causing gains in the value of the stock and prompting our partners at Trade Ideas to alert us to the movement. At the moment (8:57), AKTX is trading at $6.50 per share after a gain of 16.28% thus far today.





AKTX Gains On Regulatory Update

As mentioned above, Akari Therapeutics is having an overwhelmingly strong start to the trading session this morning after announcing that, following a recent Type B End of Phase II Meeting with the FDA, the company plans to advance CoversinTM toward Phase III clinical studies. The treatment is being studied as an option for patients with Paroxysma Noctumal Hemoglobinuria, also known as PNH. It is expected that the Phase III study surrounding the treatment will start in the first quarter of 2018.

In the FDA meeting, the FDA indicated to AKTX that providing safety and efficacy data from the company’s clinical trials for the proposed number of unique PNH patients on Coversin for more than one year seems to be reasonable. Of course, this opinion is subject to review of the hard data upon submission. In a statement, Dr. David Horn Solomon, CEO at AKTX, had the following to offer:




Following our recent FDA meeting, we are working to initiate a Phase III clinical trial of Coversin in PNH in Q1 2018… We will continue to work closely with the FDA, benefitting from our Fast Track status in the U.S., and with the EMA towards resubmission of a BLA and MMA, respectively, for Coversin in PNH.

Akari continues to build momentum in its complement focused therapy by advancing Coversin towards Phase III in PNH and Phase II in aHUS. With Coversin delivered subcutaneously, patients may have greater independence due to self-administration. Phase II studies are also planned for a number of other indications where Coversin’s actions on both the complement and leukotriene (LTB4) pathways play a role. It’s two leading targets in this area area atopic keratoconjunctivitis (AKC), a rare eye disorder and severe bullous pemphigoid (BP), a rare skin disorder.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on AKTX. In particular, we’ll be following the ongoing work with regard to Coversin and are excited to see the results of the Phase III clinical trial. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 338
Cancer Genetics CGIX Stock News

Cancer Genetics Inc (NASDAQ: CGIX) announced some incredibly positive news with regard to the combination trial surrounding immuno-oncology agents. The company announced that it has closed its 25th contract surrounding the topic. Here’s what we saw from the PR…





CGIX Announces 25th Contract Win Surrounding Immuno-Oncology Agents

As mentioned above, Cancer Genetics released some big news this morning. The company announced that it has officially closed its 25th contract that supports a drug combination trial for immuno-oncology agents. The combination trials on the center stage are with leading pharmaceutical or biotechnology companies that are focused on providing biomarker based testing, companion diagnostic services or new test development for patient measurement and monitoring where an immuno-oncology drug is being used with another oncology therapy.




CGIX informed investors that the majority of the trials surround testing for multiple types of markers, including immune-markers like PD-1, PD-L1, and CTLA-4 as well as other targeted genomic markers. The goal is ultimately to further understand the potential for patient response and to monitor therapy effectiveness. In a statement, Panna Sharma, President and CEO at CGIX, had the following to offer…

Achieving the goal of closing 25 leading-edge I-O combination clinical trial contracts is a major milestone for our Company and a testament to the depth and quality of our portfolio and the capabilities of our team members… Combination approaches in oncology therapy not only present a potentially dramatic advancement for cancer patient care, but also introduce new complexities in diagnostic testing, measurement, monitoring, safety, and data analysis in the clinical trial setting. With nearly half – 25 of the over 50 I-O clinical trials that we support being combination trials measuring multiple biomarkers and pathways, we are well positioned to partner with leading global pharmaceutical companies in bringing innovative cancer treatments to patients.

Combination oncology trials now demand measuring and monitoring beyond genomics, and integrated data from proteomics, immunophenotyping and cellular interactions. We believe as the range and complexity of combination therapies increase, biotech and pharma companies will have the need to partner with innovative companies that can combine innovative new technologies as part of study design and early development, and also deliver industrial-scale, clinical ready tests for patient monitoring and diagnostic use once the therapies are approved. CGI has been uniquely poised to provide this integrated, bench to bedside capability; one that is exceptional in the landscape of oncology providers.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on CGIX. In particular, we’re interested in following the story surrounding the ongoing success of the company’s biomarker testing. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 300
Advanced Medical Isotope Corporation ADMD Stock News

Advanced Medical Isotope Corp. (OTCMKTS: ADMD) is having a relatively strong start to the trading session this morning after announcing that it would be offering a presentation relatively soon. At the moment (11:15), ADMD is trading at $0.066 after a gain of $0.46% thus far today.





ADMD Gains After Announcing Coming Presentation

As mentioned above, Advanced Medical Isotope is having a relatively strong start to the trading session today after annuncing that they will be presenting at this year’s MicroCap Conference. The presentation will be held on October 5th in New York City.




This is great news as it will likely open doors for ADMD. In fact, the MicroCap Conference is an exclusive event designed for companies to offer presentations to investors who specialize in small and microcap stocks. As a result of being part of the conference, the company will have the opportunity to have meetings with various microcap investors, bringing their company to the spotlight of center stage in one of the most important conferences for companies of this caliper.

The conference will take place in New York City at the Essex House on October 5h. Registration for the event will start on Thursday of at 7:00 AM and will last through the evening. The conference will offer attendees various company sessions, presentations, good food, and time to work with other investors over drinks. If you’d like to register for the conference, click here!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ADMD. In particular, we’re interested in following the news surrounding the presentation and excited to see the results of the presentation with regard to bringing in new investors. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 6573
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...